...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiology >Hepatic enhancement and metastatic lesion conspicuity on CT scans: influence of intravenous glucagon and oral CT contrast material.
【24h】

Hepatic enhancement and metastatic lesion conspicuity on CT scans: influence of intravenous glucagon and oral CT contrast material.

机译：肝脏增强和转移灶明显的CT扫描：静脉内胰高血糖素和口服CT对比剂的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To determine the effect of glucagon and orally administered contrast material on hepatic enhancement and metastatic lesion conspicuity on computed tomographic (CT) scans. MATERIALS AND METHODS: Nine patients with a history of hepatic metastasis underwent two CT examinations with intravenously administered contrast material. Each patient was given orally administered CT contrast material for the first examination. No oral contrast material was given in the second examination. Five patients underwent the initial CT with intravenous administration of 1 mg of glucagon; the second examination was performed without glucagon. Four patients were administered glucagon before the second examination, but no glucagon was administered before the first. Attenuation in the liver, portal vein, and aorta was measured by observers blinded to whether the patient had been given glucagon. Lesion conspicuity was rated on a continuous scale. RESULTS: Greater mean hepatic enhancement was noted on scans of patients inwhom oral contrast material was administered (mean, 52 HU) versus those in whom no oral contrast material was administered (mean, 47 HU; P = .019). Glucagon was not associated with greater hepatic enhancement. Neither oral contrast material nor glucagon had a significant effect on lesion conspicuity. CONCLUSION: Oral CT contrast material is associated with a small increase in hepatic enhancement that does not appear to be clinically important. Glucagon does not appear to affect hepatic enhancement or lesion conspicuity in humans.
机译：目的：确定胰高血糖素和口服对比剂对计算机断层扫描（CT）扫描对肝脏增强和转移灶明显的影响。材料与方法：9例有肝转移史的患者接受了两次CT检查，静脉注射造影剂。第一次检查时，给每位患者口服CT对比剂。在第二次检查中未给予口服对比剂。 5例患者接受了最初的CT静脉注射1 mg胰高血糖素治疗。第二次检查没有胰高血糖素。在第二次检查之前，有四名患者接受了胰高血糖素的治疗，但是在第一次检查前没有给予胰高血糖素。肝脏，门静脉和主动脉的衰减是由观察者测量的，该观察者对患者是否接受了胰高血糖素视而不见。病变显着性以连续量表评分。结果：与未使用口服对比剂的患者相比，未使用口服对比剂的患者（平均52 HU）的扫描显示肝脏平均增强程度更高（平均47 HU; P = .019）。胰高血糖素与更大的肝功能增强无关。口服对比剂和胰高血糖素对病变的明显性均无显着影响。结论：口服CT造影材料与肝脏增强小幅增加有关，这在临床上似乎并不重要。胰高血糖素似乎不影响人类的肝功能增强或病变明显。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号